The promises of Treg
autoimmune therapy,all in one hand

The largest, most advanced pipeline of cell therapies for autoimmune disease.

Company deck

About PolTREG

Three clinical assets that will deliver value and milestones

PTG007, a potential disease-modifying treatment for Type-1 Diabetes and Multiple Sclerosis

Leading contender in quest for engineered Tregs

Expects to be first-in-class in launching in-patient trials in CAR-Tregs in MS and Amyotrophic Lateral Sclerosis (ALS)

World-class manufacturing expertise in own facilities

17 years of experience, first company ever to administer Tregs a patient


benefiting patients

Tregs are on their way to become routine treatment for autoimmune diseases and to become a new class of disease-modifying therapeutics.


growth market

Treg therapies offer vast commercial potential, with potential peak sales for PTG-007 estimated at $1.9 billion for newly diagnosed T1D.